Immuron (NASDAQ:IMRN) achieved record first-half sales for its lead commercial product, Travelan®, reporting a 5% year-over-year increase in global revenue to AUD$4.2 million.
The results, announced Monday, underscore a sustained recovery in the global travel sector and the success of the company’s pivot toward digital-first consumer marketing.
Australia remains the company’s primary revenue driver, contributing AUD$3.3 million to the half-year total—a 13% increase over the same period last year.
The growth came despite a "one-off" reduction in inventory levels following the high-profile merger of major pharmacy distributors Sigma Healthcare and Chemist Warehouse, which temporarily suppressed wholesale orders.
In the United States, sales surged 17% to AUD$0.9 million.
Management attributed the U.S. momentum to an aggressive expansion of social media promotions and new store listings on Amazon and specialized travel health networks.
While Canadian sales faced a steep 85% decline for the half-year due to prior year stocking anomalies, the region showed signs of a sharp turnaround in the second quarter, with sales jumping 191% on a quarter-on-quarter basis.